Weigao Group Co., Ltd., a well-known medical device brand, was founded in 1988, a famous trademark in Shandong Province, and a medical system solution provider focusing on disposable medical devices and pharmaceuticals
Weigao Group Co., Ltd. was founded in 1988, with disposable medical devices and pharmaceuticals as its main business, vigorously developing the real estate industry, expanding the tourism and catering service industry, steadily developing the financial industry, and implementing multi-industry simultaneous development and linkage development. Under the jurisdiction of medical products, blood purification, orthopedics, biotechnology, pharmaceutical, cardiac consumables, medical business, real estate, finance and other 9 industrial groups, more than 50 subsidiaries, medical equipment and drugs mainly include infusion consumables, blood transfusion equipment, cardiac consumables, indwelling needles and various special-shaped needles, blood purification equipment and consumables, orthopedic materials, surgical equipment and accessories, trauma care, surgical robots, minimally invasive instruments and equipment, ICU products and accessories, large-volume injections and other drugs, renal products, biological diagnostic reagents, More than 50 series, more than 500 varieties, more than 80,000 specifications, total assets of more than 40 billion yuan, covering an area of more than 6 million square meters, and more than 2.6 million square meters of purification workshop. Become the world's leading manufacturer of medical system solutions with complete varieties, safety and reliability, trustworthiness and China. It has actively entered the field of medical health and services, carried out kidney dialysis services, and established dozens of kidney dialysis centers across the country. Shandong Weigao Group Medical Polymer Products Co., Ltd., a holding subsidiary of the Group, is a listed company in Hong Kong. Weihai Blue Ocean Bank was approved by the China Banking Regulatory Commission and is the first private bank in the province.
The group is a national 863 industrialization base, a key high-tech enterprise of the National Torch Program, and has won the China Industry Award (the only award-winning enterprise in the industry), the industry's leading enterprise, the national contract-abiding and trustworthy enterprise, the national independent innovation demonstration unit, the national advanced collective for helping the disabled, the national May Day Labor Award, the advanced unit of China's enterprise culture construction, the excellent unit of China's corporate culture top-level design and grassroots practice, the national advanced enterprise for the implementation of excellent performance model, the Chinese patent Shandong star enterprise, and the national technological innovation demonstration enterprise , the first place of China's most powerful medical device brand supplier, the second Governor Quality Award of Shandong Province, the Outstanding Contribution Award of Industry-University-Research Cooperation and Innovation in Shandong Province, the Outstanding Contribution Award of Shandong Industry, and the Special Contribution Award of Shandong Public Welfare for the Disabled.
Weigao insists on adjusting the product structure with technological innovation and vigorously improving the ability of independent innovation. It has established a national enterprise technology center, a national engineering laboratory for implantable devices, a national innovation pilot enterprise, an academician workstation, a postdoctoral workstation, a high-performance medical device research center in Shandong Province, a medical device technology innovation center in Shandong Province, a provincial engineering technology research center, Taishan Scholar Laboratory and other innovation platforms, and has cooperated with the Chinese Academy of Sciences, the Chinese Academy of Engineering, the Academy of Military Medical Sciences, 301 Hospital, the second, third and fourth military medical universities, Harbin Institute of Technology, Tianjin University, Zhejiang University, Sichuan University, East China University of Science and Technology, University of Aeronautics and Astronautics and other units have carried out industry-university-research cooperation, established more than 30 R&D centers or joint laboratories, and set up R&D institutions in Beijing, Tianjin, Changchun and Shenzhen, with 4,000 R&D and management personnel. Now it has more than 150 invention patents, more than 600 products with independent intellectual property rights, more than 80% of high-tech content and high value-added products, of which more than 120 products have reached the international advanced and domestic leading level, orthopedic instruments, dialyzers, cardiac stents, artificial liver, automatic chemiluminescence analyzer, color ultrasound, DRX optical machine, prefilled syringe, membrane oxygenator, protein A immunoadsorption column and other more than 100 products to break the foreign monopoly, 30 products included in the National Torch Program, the national "863" He has won the second prize of National Science and Technology Progress Award and 3 second prizes of Technology Progress Award. Weigao Postdoctoral Research Workstation was rated as an excellent postdoctoral research station in Shandong Province by Shandong Provincial Department of Human Resources and Social Security. Wego Miaoshou S Minimally Invasive Surgical Robot won the National Excellent Industrial Design Gold Award and is the only concept award.
Adhere to scientific management, implement the excellent performance evaluation criteria, establish a quality standard system under the concept of large quality, continuously improve the operation and management model, improve customer satisfaction, and enhance competitiveness. Promote flat management and introduce advanced management ideas and methods. The implementation of ERP, SRM, BPM and other information systems, to create a complete information management platform, improve the level of decision-making, management efficiency and quality. Adhere to the quality policy of "satisfying and striving to exceed the maximum needs of customers" and pursue customer satisfaction. It is the first in the industry to pass the ISO9000 certification, 3C, CMD, ISO13485 quality system certification, EU CE certification, GMP certification, etc., and more than 30 products have been recognized by the US FDA. Vigorously implement the famous brand strategy, produce high-quality products with advanced technology, provide first-class services, and win market recognition. The products are sold to more than 30 provinces and municipalities in China, and to about 100 countries and regions in the world. The national coverage rate of tertiary hospitals has reached 83%, the coverage rate of blood stations has reached about 80%, the market share of high-end infusion consumables, blood bags, prefilled syringes and other products is about 80%, and the market share of orthopedic series, blood purification series and cardiac consumables series products is about 30%.
Wego adheres to the implementation of the "going out" strategy and strengthens international cooperation. In 2004, Weigao shares were listed on the Growth Enterprise Market of Hong Kong, and in 2010, they were listed on the main board, opening up a new platform for financing. It has successively established strategic cooperative relations with well-known foreign enterprises such as the World Bank, Medtronic Corporation of the United States, Nikkiso Co., Ltd. of Japan, Terumo Co., Ltd. of Japan, True Vision Corporation of the United States, and IT companies of South Korea, and has established R&D centers in the United States, Japan, the United Kingdom, Germany and France to absorb global advanced medical technology and improve the ability of independent innovation.
Wego insists on social responsibility, vigorously supports social welfare and charity, and promotes the construction of a harmonious society. It has successively carried out activities such as Weigao Bright Action, Weigao Love Project, Weigao Life Relay Project, Weigao Student Aid Activities, Weigao Love Top Ten Filial Piety Star Selection Activities, Pledge Charity Fund, and Support for Disaster Areas, and at the same time vigorously support schools, poor villages, poor workers, poor families, and poor students, with a total of more than 400 million yuan in donations and materials. Since its launch in September 2004, the Wego Bright Action has provided free vision surgery for more than 15,000 cataract patients. Donated 10 million yuan to the Institute of Barrier-free Development of Tsinghua University to set up China's first barrier-free fund, the China Barrier-free Love Award, and awarded the award for the first time for the construction of social aging and national barrier-free; donated 10 million yuan to set up a scoliosis relief fund to help poor children; Donated 1.7 million yuan to the China Disabled Persons Art Troupe, the Chinese Paralympic Games, and the China Guide Dog Base. Internally, more than 100 employees in difficulty have been donated; More than 80 children of employees who were admitted to universities were rewarded.
Weigao will always adhere to the factory construction policy of "pioneering and innovative, realistic and consolidating", adhering to the mission of "working with the messenger in white to create a healthy future", establish the core values of conscience, sincerity and loyalty, adhere to the strategic policy of "one center, three adjustments", build China's first-class management team, China's first-class engineer expert team, China's first-class sales team, China's first-class corporate culture, actively transform the mode of economic growth, continue to improve the ability of independent innovation, and integrate R&D resources at a higher level. Adhere to the research and development of high-tech new products, and strive to make major breakthroughs in technology and research and development in key fields such as medical devices and pharmaceuticals; Based on the domestic and international markets, taking international cooperation as an opportunity, we will gradually realize the all-round docking of management concepts, operating mechanisms, human resources, technology, products, markets, etc., strengthen cooperation, integrate and advance together, improve the core competitiveness of enterprises, and strive to build a global company, achieve sales revenue of 100 billion yuan by 2020, and strive to achieve the vision and goal of "entering the world's strongest enterprises, leading in Asia, the strongest and most respected medical device and pharmaceutical enterprises in China".
